Zepbound launched in the US in November 2023 for adults with obesity or overweight with at least one weight-related comorbidity
A new signal: dysesthesia with retatrutide The TRIUMPH-4 Phase 3 trial revealed a side effect not previously highlighted in earlier data
At En Vogue IV Therapy & Wellness, our team will evaluate your medical history, current health conditions, and weight loss goals to determine if Tirzepatide is the right solution for you
Analytical studies usually include peptide mapping, impurity profiling, degradation analysis, structural characterization, stability testing, and comparative studies with the reference listed drug
No dose adjustment is required for patients with mild, moderate or severe liver disease